Outcome of Ahmed glaucoma valve implant in congenital fibrovascular pupillary membrane with secondary glaucoma

Abstract Background Congenital fibrovascular pupillary membranes in secondary glaucoma (CFPMSG) is kind of refractory childhood glaucoma. The aim of the study is to evaluate the efficacy and safety of Ahmed glaucoma valve (AGV) implants in CFPMSG. Methods Twelve patients with CFPMSG who underwent an...

Full description

Saved in:
Bibliographic Details
Main Authors: Yingting Zhu, Shufen Lin, Lei Fang, Liming Chen, Pingping Liu, Yimin Zhong, Xing Liu
Format: Article
Language:English
Published: BMC 2025-03-01
Series:BMC Ophthalmology
Subjects:
Online Access:https://doi.org/10.1186/s12886-025-03980-6
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849392318949359616
author Yingting Zhu
Shufen Lin
Lei Fang
Liming Chen
Pingping Liu
Yimin Zhong
Xing Liu
author_facet Yingting Zhu
Shufen Lin
Lei Fang
Liming Chen
Pingping Liu
Yimin Zhong
Xing Liu
author_sort Yingting Zhu
collection DOAJ
description Abstract Background Congenital fibrovascular pupillary membranes in secondary glaucoma (CFPMSG) is kind of refractory childhood glaucoma. The aim of the study is to evaluate the efficacy and safety of Ahmed glaucoma valve (AGV) implants in CFPMSG. Methods Twelve patients with CFPMSG who underwent anterior chamber reconstruction (ASR) with a stable anterior chamber but uncontrolled intraocular pressure (IOP) underwent AGV implantation. Patients with a follow-up period of > 12 months were enrolled. Demographic data were collected. All patients underwent comprehensive ophthalmic examinations before and after surgeries, including IOP measurement, A- and B-scan ultrasonography, and ultrasound biomicroscopy (UBM), etc. Success was defined as postoperative intraocular pressure (IOP) ≤ 21 mmHg with (qualified success) or without (complete success) the use of glaucoma drugs. Results The median age of enrolled patients was 15.1 ± 12.5 months old (range 4.5–46) and 58.3% of them were female. At last follow-up (32.0 ± 16.0 months), the average IOP was declined (postoperative: 18.7 ± 4.5 mmHg vs. preoperative: 29.0 ± 4.0 mmHg, p < 0.001). The number of glaucoma drugs decreased from 3 (range 2–3) to 1.5 (range 0–3) (P < 0.001), while the anterior chamber depth (ACD) remained stable (3.21 ± 0.70 mm and 3.40 ± 0.82 mm, respectively) (p = 0.57) after AGV implantation. The complete success rate was 25% (3/12) and the qualified success rate was 58.3% (7/12). The total success rate was 83.8%. No severe complications were noted. Conclusions This study demonstrated that AGV implants could be safe and effective for CFPMSG with uncontrolled IOP. AGV implantation is a feasible option for the treatment of CFPMSG.
format Article
id doaj-art-9ab35ac2f00048aabf094e5e0f601c11
institution Kabale University
issn 1471-2415
language English
publishDate 2025-03-01
publisher BMC
record_format Article
series BMC Ophthalmology
spelling doaj-art-9ab35ac2f00048aabf094e5e0f601c112025-08-20T03:40:47ZengBMCBMC Ophthalmology1471-24152025-03-012511710.1186/s12886-025-03980-6Outcome of Ahmed glaucoma valve implant in congenital fibrovascular pupillary membrane with secondary glaucomaYingting Zhu0Shufen Lin1Lei Fang2Liming Chen3Pingping Liu4Yimin Zhong5Xing Liu6State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Provincial Clinical Research Center for Ocular Diseases, Sun Yat-sen UniversityState Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Provincial Clinical Research Center for Ocular Diseases, Sun Yat-sen UniversityState Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Provincial Clinical Research Center for Ocular Diseases, Sun Yat-sen UniversityState Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Provincial Clinical Research Center for Ocular Diseases, Sun Yat-sen UniversityState Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Provincial Clinical Research Center for Ocular Diseases, Sun Yat-sen UniversityState Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Provincial Clinical Research Center for Ocular Diseases, Sun Yat-sen UniversityState Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Provincial Clinical Research Center for Ocular Diseases, Sun Yat-sen UniversityAbstract Background Congenital fibrovascular pupillary membranes in secondary glaucoma (CFPMSG) is kind of refractory childhood glaucoma. The aim of the study is to evaluate the efficacy and safety of Ahmed glaucoma valve (AGV) implants in CFPMSG. Methods Twelve patients with CFPMSG who underwent anterior chamber reconstruction (ASR) with a stable anterior chamber but uncontrolled intraocular pressure (IOP) underwent AGV implantation. Patients with a follow-up period of > 12 months were enrolled. Demographic data were collected. All patients underwent comprehensive ophthalmic examinations before and after surgeries, including IOP measurement, A- and B-scan ultrasonography, and ultrasound biomicroscopy (UBM), etc. Success was defined as postoperative intraocular pressure (IOP) ≤ 21 mmHg with (qualified success) or without (complete success) the use of glaucoma drugs. Results The median age of enrolled patients was 15.1 ± 12.5 months old (range 4.5–46) and 58.3% of them were female. At last follow-up (32.0 ± 16.0 months), the average IOP was declined (postoperative: 18.7 ± 4.5 mmHg vs. preoperative: 29.0 ± 4.0 mmHg, p < 0.001). The number of glaucoma drugs decreased from 3 (range 2–3) to 1.5 (range 0–3) (P < 0.001), while the anterior chamber depth (ACD) remained stable (3.21 ± 0.70 mm and 3.40 ± 0.82 mm, respectively) (p = 0.57) after AGV implantation. The complete success rate was 25% (3/12) and the qualified success rate was 58.3% (7/12). The total success rate was 83.8%. No severe complications were noted. Conclusions This study demonstrated that AGV implants could be safe and effective for CFPMSG with uncontrolled IOP. AGV implantation is a feasible option for the treatment of CFPMSG.https://doi.org/10.1186/s12886-025-03980-6Congenital fibrovascular pupillary membraneSecondary glaucomaAhmed glaucoma valve implantation
spellingShingle Yingting Zhu
Shufen Lin
Lei Fang
Liming Chen
Pingping Liu
Yimin Zhong
Xing Liu
Outcome of Ahmed glaucoma valve implant in congenital fibrovascular pupillary membrane with secondary glaucoma
BMC Ophthalmology
Congenital fibrovascular pupillary membrane
Secondary glaucoma
Ahmed glaucoma valve implantation
title Outcome of Ahmed glaucoma valve implant in congenital fibrovascular pupillary membrane with secondary glaucoma
title_full Outcome of Ahmed glaucoma valve implant in congenital fibrovascular pupillary membrane with secondary glaucoma
title_fullStr Outcome of Ahmed glaucoma valve implant in congenital fibrovascular pupillary membrane with secondary glaucoma
title_full_unstemmed Outcome of Ahmed glaucoma valve implant in congenital fibrovascular pupillary membrane with secondary glaucoma
title_short Outcome of Ahmed glaucoma valve implant in congenital fibrovascular pupillary membrane with secondary glaucoma
title_sort outcome of ahmed glaucoma valve implant in congenital fibrovascular pupillary membrane with secondary glaucoma
topic Congenital fibrovascular pupillary membrane
Secondary glaucoma
Ahmed glaucoma valve implantation
url https://doi.org/10.1186/s12886-025-03980-6
work_keys_str_mv AT yingtingzhu outcomeofahmedglaucomavalveimplantincongenitalfibrovascularpupillarymembranewithsecondaryglaucoma
AT shufenlin outcomeofahmedglaucomavalveimplantincongenitalfibrovascularpupillarymembranewithsecondaryglaucoma
AT leifang outcomeofahmedglaucomavalveimplantincongenitalfibrovascularpupillarymembranewithsecondaryglaucoma
AT limingchen outcomeofahmedglaucomavalveimplantincongenitalfibrovascularpupillarymembranewithsecondaryglaucoma
AT pingpingliu outcomeofahmedglaucomavalveimplantincongenitalfibrovascularpupillarymembranewithsecondaryglaucoma
AT yiminzhong outcomeofahmedglaucomavalveimplantincongenitalfibrovascularpupillarymembranewithsecondaryglaucoma
AT xingliu outcomeofahmedglaucomavalveimplantincongenitalfibrovascularpupillarymembranewithsecondaryglaucoma